SecBot SecBot
144 ·Filed Sep 23, 2026

KRSA

Korsana Biosciences, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed1mo ago SEC0001950047-26-009776
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

Monitor whether the sale is actually executed on Form 4; a director selling a modest number of vested RSU shares is routine and not indicative of negative outlook. No immediate catalyst.

DirectionNeutral
Confidencemedium
Horizondays
Latest settled: T+20d ⚠ clustered
KRSA ▼ -10.11% at T+20d
NEUTRAL call -10.11% · α vs SPY -9.69% · entry $37.19 → $33.43
Next anchor: T+60d in 7w
Latest observation: T+21 -21.57% FF3 residual α
Entry = T+0 close
Sep 23, 2026
via day close
T+1d
-16.64%
call -16.64% · α -17.19%
$31.00
settled 5w ago
T+5d
-16.11%
call -16.11% · α -15.69%
$31.20
settled 28d ago
T+20d
-10.11%
call -10.11% · α -9.69%
$33.43
settled 7d ago
T+60d
Pending
in 7w

Price Chart

Loading chart...

Executive Summary

Director Errol B. De Souza filed a Form 144 to sell 4,903 shares of Korsana Biosciences common stock, with an approximate market value of $171,556. The shares were acquired via restricted stock vesting between October 2024 and July 2026. The filing signals an intent to sell, though the sale may not be executed.

Key Facts

  • Filer: Director Errol B. De Souza
  • Proposed sale: 4,903 shares of common stock
  • Estimated value: $171,555.97
  • Shares acquired via restricted stock vesting from 10/01/2024 through 07/16/2026
  • Broker: Morgan Stanley Smith Barney LLC Executive Financial Services
  • Filing date: 09/23/2026

Financial Impact

Proposed sale of 4,903 shares valued at approximately $171,556 — small relative to typical insider holdings and market cap; no material financial impact.

dilution

Risk Factors

  • Insider selling could be perceived negatively if followed by additional large sales
  • No market data or company financials provided to contextualize the sale

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-009776
Document: 0001950047-26-009776-index.html0001950047-26-009776
Document: 0001950047-26-009776.txt0001950047-26-009776
8 reports for KRSA
Performance horizon
Filters
Rows
Reports for KRSA, sortable and filterable
TypeNow
Oct 22, 2026
5d ago
144
NEUTRAL ★ 2/10
$31.31awaiting T+20awaiting T+20$30.07 (−3.96%)
Oct 15, 2026
12d ago
SC 13G/A
NEUTRAL ★ 2/10
$32.38awaiting T+20awaiting T+20$30.07 (−7.13%)
Oct 15, 2026
12d ago
DEF 14A
NEUTRAL ★ 5/10
$32.38awaiting T+20awaiting T+20$30.07 (−7.13%)
Sep 23, 2026
4w ago
144
NEUTRAL ★ 2/10
$37.19 $33.43▼ −10.11%▼ −9.69%$30.07 (−19.14%)
Sep 22, 2026
5w ago
144
NEUTRAL ★ 1/10
$32.30 $32.54▲ +0.74%▲ +0.06%$30.07 (−6.90%)
Sep 18, 2026
5w ago
SC 13G
NEUTRAL ★ 4/10
$33.21 $31.41▼ −5.42%▼ −4.51%$30.07 (−9.45%)
Sep 18, 2026
5w ago
144
NEUTRAL ★ 2/10
$33.21 $31.41▼ −5.42%▼ −4.51%$30.07 (−9.45%)
Sep 16, 2026
5w ago
SC 13G
NEUTRAL ★ 3/10
$31.23 $34.32▲ +9.89%▲ +7.83%$30.07 (−3.71%)
Showing 8 of 8

US Market Status

Market Closed · Opens in 5h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 23, 2026